Compare KLA Corp. (KLAC) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Tilray Brands Inc — how do they compare? KLA Corp. trades at $195.95 (market cap $256.72B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: KLA Corp. is far larger — about 483.9× Tilray Brands Inc's market cap, and KLA Corp. pays a 0.47% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Tilray Brands Inc for 31 Days on average.
| KLAC | TLRY | |
|---|---|---|
Market Cap | $256.72B | $530.54M |
Volume | 9,970,753 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $301.71 | $21.00 |
52-Week Low | $98.28 | $3.57 |
Typical Hold Time | 60 Days | 31 Days |
Enterprise Value | $257.97B | $684.46M |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $195.57, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $193. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, revenue growth accelerating to $12.16B in 2025, and exceptional profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57B backlog and competitive positioning against AMAT and ASML.
KLA presents a compelling growth opportunity with analyst consensus price target of $223.88 (14.5% upside) and strong institutional support, though elevated valuation ratios (P/E 53.75, P/S 19.12) and semiconductor cycle sensitivity warrant caution. The stock's outlook remains positive driven by AI infrastructure spending and advanced packaging growth, with key risks including competition intensity and potential margin pressure from increased investments.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
